828 related articles for article (PubMed ID: 25986884)
1. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development.
Bailo R; Bhatt A; Aínsa JA
Biochem Pharmacol; 2015 Aug; 96(3):159-67. PubMed ID: 25986884
[TBL] [Abstract][Full Text] [Related]
2. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI
Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828
[TBL] [Abstract][Full Text] [Related]
3. 1
Korycka-Machała M; Viljoen A; Pawełczyk J; Borówka P; Dziadek B; Gobis K; Brzostek A; Kawka M; Blaise M; Strapagiel D; Kremer L; Dziadek J
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332069
[TBL] [Abstract][Full Text] [Related]
4. The Mycobacterium tuberculosis MmpL11 Cell Wall Lipid Transporter Is Important for Biofilm Formation, Intracellular Growth, and Nonreplicating Persistence.
Wright CC; Hsu FF; Arnett E; Dunaj JL; Davidson PM; Pacheco SA; Harriff MJ; Lewinsohn DM; Schlesinger LS; Purdy GE
Infect Immun; 2017 Aug; 85(8):. PubMed ID: 28507063
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis.
Wells RM; Jones CM; Xi Z; Speer A; Danilchanka O; Doornbos KS; Sun P; Wu F; Tian C; Niederweis M
PLoS Pathog; 2013 Jan; 9(1):e1003120. PubMed ID: 23431276
[TBL] [Abstract][Full Text] [Related]
6. Acetylation of trehalose mycolates is required for efficient MmpL-mediated membrane transport in Corynebacterineae.
Yamaryo-Botte Y; Rainczuk AK; Lea-Smith DJ; Brammananth R; van der Peet PL; Meikle P; Ralton JE; Rupasinghe TW; Williams SJ; Coppel RL; Crellin PK; McConville MJ
ACS Chem Biol; 2015 Mar; 10(3):734-46. PubMed ID: 25427102
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of MmpS5 and MmpL5 Contributes to Both Efflux Transporter MmpL5 Trimerization and Drug Resistance in Mycobacterium tuberculosis.
Yamamoto K; Nakata N; Mukai T; Kawagishi I; Ato M
mSphere; 2021 Jan; 6(1):. PubMed ID: 33408221
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. I3-Ag85 effect on phthiodiolone dimycocerosate synthesis.
Rens C; Laval F; Wattiez R; Lefèvre P; Dufrasne F; Daffé M; Fontaine V
Tuberculosis (Edinb); 2018 Jan; 108():93-95. PubMed ID: 29523333
[TBL] [Abstract][Full Text] [Related]
10. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
11. MmpL3 inhibitors as antituberculosis drugs.
Shao M; McNeil M; Cook GM; Lu X
Eur J Med Chem; 2020 Aug; 200():112390. PubMed ID: 32447196
[TBL] [Abstract][Full Text] [Related]
12. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
[TBL] [Abstract][Full Text] [Related]
13. Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design.
Singh G; Kumar A; Maan P; Kaur J
Curr Drug Targets; 2017 Nov; 18(16):1904-1918. PubMed ID: 28699515
[TBL] [Abstract][Full Text] [Related]
14. Transport mechanism of Mycobacterium tuberculosis MmpL/S family proteins and implications in pharmaceutical targeting.
Ma S; Huang Y; Xie F; Gong Z; Zhang Y; Stojkoska A; Xie J
Biol Chem; 2020 Feb; 401(3):331-348. PubMed ID: 31652116
[TBL] [Abstract][Full Text] [Related]
15. Insights into the smooth-to-rough transitioning in Mycobacterium bolletii unravels a functional Tyr residue conserved in all mycobacterial MmpL family members.
Bernut A; Viljoen A; Dupont C; Sapriel G; Blaise M; Bouchier C; Brosch R; de Chastellier C; Herrmann JL; Kremer L
Mol Microbiol; 2016 Mar; 99(5):866-83. PubMed ID: 26585558
[TBL] [Abstract][Full Text] [Related]
16. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
McNeil MB; O'Malley T; Dennison D; Shelton CD; Sunde B; Parish T
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055263
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium tuberculosis transporter MmpL7 is a potential substrate for kinase PknD.
Pérez J; Garcia R; Bach H; de Waard JH; Jacobs WR; Av-Gay Y; Bubis J; Takiff HE
Biochem Biophys Res Commun; 2006 Sep; 348(1):6-12. PubMed ID: 16879801
[TBL] [Abstract][Full Text] [Related]
18. MmpS5/MmpL5 as an efflux pump in Mycobacterium species.
Briffotaux J; Huang W; Wang X; Gicquel B
Tuberculosis (Edinb); 2017 Dec; 107():13-19. PubMed ID: 29050760
[TBL] [Abstract][Full Text] [Related]
19. Targeting MmpL3 for anti-tuberculosis drug development.
Bolla JR
Biochem Soc Trans; 2020 Aug; 48(4):1463-1472. PubMed ID: 32662825
[TBL] [Abstract][Full Text] [Related]
20. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
